Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.25
CCEL's Cash to Debt is ranked lower than
53% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 0.33 vs. CCEL: 0.25 )
Ranked among companies with meaningful Cash to Debt only.
CCEL' s Cash to Debt Range Over the Past 10 Years
Min: 0.17  Med: No Debt Max: No Debt
Current: 0.25
Equity to Asset -0.97
CCEL's Equity to Asset is ranked lower than
99% of the 248 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. CCEL: -0.97 )
Ranked among companies with meaningful Equity to Asset only.
CCEL' s Equity to Asset Range Over the Past 10 Years
Min: -1.05  Med: -0.11 Max: 0.92
Current: -0.97
-1.05
0.92
Interest Coverage 0.39
CCEL's Interest Coverage is ranked lower than
98% of the 213 Companies
in the Global Medical Care industry.

( Industry Median: 7.76 vs. CCEL: 0.39 )
Ranked among companies with meaningful Interest Coverage only.
CCEL' s Interest Coverage Range Over the Past 10 Years
Min: 0.39  Med: 2.12 Max: 2.6
Current: 0.39
0.39
2.6
F-Score: 4
Z-Score: -0.98
M-Score: -3.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 1.81
CCEL's Operating margin (%) is ranked lower than
75% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 6.84 vs. CCEL: 1.81 )
Ranked among companies with meaningful Operating margin (%) only.
CCEL' s Operating margin (%) Range Over the Past 10 Years
Min: -26.76  Med: 3.71 Max: 18.83
Current: 1.81
-26.76
18.83
Net-margin (%) -10.19
CCEL's Net-margin (%) is ranked lower than
88% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 4.82 vs. CCEL: -10.19 )
Ranked among companies with meaningful Net-margin (%) only.
CCEL' s Net-margin (%) Range Over the Past 10 Years
Min: -35.1  Med: -2.03 Max: 38.43
Current: -10.19
-35.1
38.43
ROA (%) -12.23
CCEL's ROA (%) is ranked lower than
91% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 3.90 vs. CCEL: -12.23 )
Ranked among companies with meaningful ROA (%) only.
CCEL' s ROA (%) Range Over the Past 10 Years
Min: -39.68  Med: -3.05 Max: 54.57
Current: -12.23
-39.68
54.57
ROC (Joel Greenblatt) (%) -241.02
CCEL's ROC (Joel Greenblatt) (%) is ranked lower than
97% of the 254 Companies
in the Global Medical Care industry.

( Industry Median: 18.74 vs. CCEL: -241.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CCEL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -241.02  Med: 72.3 Max: 245.96
Current: -241.02
-241.02
245.96
Revenue Growth (3Y)(%) 10.70
CCEL's Revenue Growth (3Y)(%) is ranked higher than
62% of the 181 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. CCEL: 10.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CCEL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -18  Med: 10.7 Max: 97.8
Current: 10.7
-18
97.8
» CCEL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with CCEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care
Compare:NAS:JYNT, OTCPK:FCHS, OTCPK:AMEH, OTCPK:MIHI, OTCPK:BNKL, OTCPK:CVHIF, AMEX:AMS, OTCPK:FDNH, OTCPK:CPAI, AMEX:SSY, OTCPK:PFHO, AMEX:HH, OTCPK:WNDM, OTCPK:LMNK, OTCPK:BICX, OTCPK:SPIN, OTCPK:USNU, OTCPK:TONJ, OTCPK:GNOW, OTCPK:CATS » details
Cryo-Cell International Inc is engaged in cellular processing & cryogenic storage. Its services include umbilical cord blood banking, umbilical cord tissue banking and umbilical cord blood & tissue banking prices.

Cryo-Cell International, Inc. was incorporated on September 11, 1989 in the State of Delaware. The Company is engaged in cellular processing and cryogenic storage, with a current focus on the collection and preservation of umbilical cord (U-Cord9(r)) blood stem cells for family use. The Company has established private family cord blood stem cell banks in terms of the number of specimens preserved. Its headquarters facility in Oldsmar, Florida handles all aspects of its U.S.-based business operations, including the processing and storage of specimens. The specimens are stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Oldsmar, Florida. It has expanded its research and development activities to develop technologies related to stem cells other than umbilical cord blood stem cells. During 2006, in parallel with its R&D associated with placental stem cells, the Company discovered novel technology related to menstrual stem cells. In November 2007, the Company announced the launch of its C'elleSM service related to this patent-pending technology, and the Company continues to focus its current research and development activities mainly on the C'elle service and related new menstrual stem cell technologies. The Company is actively marketing the C'elle service both through a bundled offer with the Company's U-Cord service and on a stand-alone basis. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, Lamaze instructors and other childbirth educators, certified nurse-midwives and other related healthcare professionals. To increase awareness among expectant parent audiences, the Company continues to promote its service in several national targeted prenatal magazines including American Baby and Fit Pregnancy, as well as several magazines distributed during childbirth classes. Expectant parents have also received information via emails and the Company has increased its internet marketing campaigns. Its competitors are Cord Blood Registry, Inc., ViaCord, a division of ViaCell, Inc., a wholly-owned subsidiary of PerkinElmer and LifeBankUSA, a division of Celgene. The Company is required to register with the FDA under the Public Health Service Act.

Ratios

vs
industry
vs
history
P/S 1.61
CCEL's P/S is ranked lower than
54% of the 238 Companies
in the Global Medical Care industry.

( Industry Median: 1.45 vs. CCEL: 1.61 )
Ranked among companies with meaningful P/S only.
CCEL' s P/S Range Over the Past 10 Years
Min: 0.28  Med: 1.33 Max: 3.13
Current: 1.61
0.28
3.13
PFCF 9.31
CCEL's PFCF is ranked higher than
89% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 23.72 vs. CCEL: 9.31 )
Ranked among companies with meaningful PFCF only.
CCEL' s PFCF Range Over the Past 10 Years
Min: 4.05  Med: 13.84 Max: 218.46
Current: 9.31
4.05
218.46
POCF 8.60
CCEL's POCF is ranked higher than
78% of the 152 Companies
in the Global Medical Care industry.

( Industry Median: 14.12 vs. CCEL: 8.60 )
Ranked among companies with meaningful POCF only.
CCEL' s POCF Range Over the Past 10 Years
Min: 3.33  Med: 12.06 Max: 277
Current: 8.6
3.33
277
Current Ratio 0.82
CCEL's Current Ratio is ranked lower than
76% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.28 vs. CCEL: 0.82 )
Ranked among companies with meaningful Current Ratio only.
CCEL' s Current Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.38 Max: 35.3
Current: 0.82
0.47
35.3
Quick Ratio 0.78
CCEL's Quick Ratio is ranked lower than
74% of the 252 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. CCEL: 0.78 )
Ranked among companies with meaningful Quick Ratio only.
CCEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.47  Med: 1.38 Max: 35.3
Current: 0.78
0.47
35.3
Days Inventory 30.01
CCEL's Days Inventory is ranked lower than
61% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 18.12 vs. CCEL: 30.01 )
Ranked among companies with meaningful Days Inventory only.
CCEL' s Days Inventory Range Over the Past 10 Years
Min: 2.07  Med: 9.79 Max: 30.01
Current: 30.01
2.07
30.01
Days Sales Outstanding 69.36
CCEL's Days Sales Outstanding is ranked lower than
78% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 42.10 vs. CCEL: 69.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
CCEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.79  Med: 51.88 Max: 73.85
Current: 69.36
25.79
73.85
Days Payable 100.97
CCEL's Days Payable is ranked higher than
74% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 38.65 vs. CCEL: 100.97 )
Ranked among companies with meaningful Days Payable only.
CCEL' s Days Payable Range Over the Past 10 Years
Min: 49.91  Med: 82.68 Max: 104.76
Current: 100.97
49.91
104.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 6.60
CCEL's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 127 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. CCEL: 6.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CCEL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -14.9  Med: -0.4 Max: 6.6
Current: 6.6
-14.9
6.6

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.22
CCEL's Price/Median PS Value is ranked lower than
66% of the 195 Companies
in the Global Medical Care industry.

( Industry Median: 1.00 vs. CCEL: 1.22 )
Ranked among companies with meaningful Price/Median PS Value only.
CCEL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 1.27 Max: 67.6
Current: 1.22
0.29
67.6
Earnings Yield (Greenblatt) (%) -6.09
CCEL's Earnings Yield (Greenblatt) (%) is ranked lower than
89% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 3.80 vs. CCEL: -6.09 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CCEL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -6.26  Med: 9.2 Max: 642.2
Current: -6.09
-6.26
642.2

More Statistics

Revenue (TTM) (Mil) $23.06
EPS (TTM) $ -0.30
Beta-0.25
Short Percentage of Float0.05%
52-Week Range $2.55 - 4.35
Shares Outstanding (Mil)6.80
» More Articles for CCEL

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Termination of a Material Definitive Agreement,... Nov 03 2016
CRYO CELL INTERNATIONAL INC Financials Oct 21 2016
Cryo-Cell International, Inc. :CCEL-US: Earnings Analysis: Q3, 2016 By the Numbers : October 19,... Oct 19 2016
Cryo-Cell Reports Fiscal Third Quarter 2016 Results Oct 18 2016
CRYO CELL INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Oct 17 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 13 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 30 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 01 2016
Cryo-Cell International, Inc. :CCEL-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016 Jul 26 2016
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Claims against... Jul 19 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 12 2016
CRYO CELL INTERNATIONAL INC Files SEC form 10-Q, Quarterly Report Jul 11 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 07 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Other Events Jul 01 2016
SHAREHOLDER ALERT: Lundin Law PC Announces Ongoing Investigation Of Cryo-Cell International, Inc.... Jun 29 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Possible Violations of... Jun 29 2016
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Investigation of Cryo-Cell International, Inc.... Jun 28 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jun 24 2016
Cryo-Cell International, Inc. :CCEL-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016 Jun 22 2016
CRYO CELL INTERNATIONAL INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an... May 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)